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Summary
Objective: To determine the effects of exercise and weight loss interventions on serum levels of four biomarkers and to examine if changes in
biomarker levels correlate with clinical outcome measures in obese and overweight adults with knee osteoarthritis (OA).
Methods: Serum was obtained at baseline, 6 and 18 months from 193 participants in Arthritis, Diet and Activity Promotion Trial. This was a sin-
gle-blind 18-month trial with subjects randomized to four groups: healthy-lifestyle (HL), diet (D), exercise (E) and diet plus exercise (DþE).
Serum levels of cartilage oligomeric matrix protein (COMP), hyaluronan (HA), antigenic keratan sulfate (AgKS), and transforming growth
factor-b1 (TGF-b1) were measured by enzyme linked immunosorbent assay.
Results: At baseline there were no signiﬁcant differences in biomarker levels between intervention groups. When results for all the intervention
groups were combined, the levels of HA were found to be negatively correlated with medial joint space width and positively correlated with
KellgreneLawrence scores (KeL scores) while TGF-b1 levels negatively correlated with KeL scores. When biomarker levels measured at
6 and 18 months were adjusted for baseline values, age, gender, and body mass index, weak but signiﬁcant differences between intervention
groups were present for mean levels of COMP and TGF-b1. Furthermore, AgKS levels averaged over all groups tended to decrease over time.
There were no signiﬁcant associations of baseline biomarkers and the follow-up outcomes. Weak associations were noted between change in
the biomarkers at 18 months and change in outcome measures that included change in weight with AgKS and COMP and change in Western
Ontario and McMaster Universities Osteoarthritis Index pain with AgKS.
Conclusion: Overall, the E and D interventions did not show a consistent effect on levels of potential OA biomarkers. The four biomarkers
showed differences in correlations with outcome measures suggesting that they may measure different aspects of disease activity in OA.
The strongest correlations were between serum HA and radiographic measures of OA at baseline.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is a progressive, painful and often dis-
abling disease characterized by the loss of articular carti-
lage, which is accompanied by bony hypertrophy within
a diarthrodial joint. Unmet needs in clinical OA studies are
the ability to detect early disease prior to radiographic
changes, to determine or predict the rate of disease pro-
gression of the joint, and to rapidly ascertain whether or
not a therapeutic intervention slows down or stops disease
progression. These needs must be effectively addressed if
the detection and management of OA are to be improved.
At present, plain radiographs are commonly used to clas-
sify OA subjects for the purposes of clinical studies and joint*Address correspondence and reprint request to: Dr Richard F.
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1047space narrowing is often used as a measure of disease
progression. Although plain radiography is, at present, the
‘‘gold standard’’ for evaluation of OA progression, it is
fraught with problems related to the accurate reproduction
of measurements of joint space width (JSW), especially in
subjects who have knee OA1e3.
Recently, researchers have gained knowledge about the
biology of OA and have identiﬁed molecular events that
lead to the destruction and remodeling of joint tissues,
including cartilage and bone4,5. Cytokines, such as interleu-
kin-1 (IL-1) and IL-6 and other inﬂammatory mediators, are
found within the cartilage and are thought to participate
locally in cartilage destruction by inhibiting matrix synthesis
and stimulating the release of degradative enzymes6,7. Spe-
ciﬁc degenerative and biosynthetic events, which have been
identiﬁed and quantiﬁed by the use of antibody-based immu-
noassays, are used to study tissue-speciﬁc changes in OA
as reﬂected by molecular biomarkers5,8,9.
Among the most promising of these biomarkers are type
II collagen degradation products, antigenic keratan sulfate
(AgKS) epitopes, cartilage oligomeric matrix protein
1048 S. D. Chua et al.: Effect of an exercise and dietary intervention on serum biomarkers(COMP), GP-39/YK-40, type I collagen cross-links, several
matrix metalloproteinases, and hyaluronan (HA)5,9,10. The
biomarkers can be detected principally in the joint tissues
where the events occur, but also in body ﬂuids, such as
peripheral blood, urine and synovial ﬂuid, into which the
biomarkers are released. Three of the most commonly
used serum biomarkers associated and/or correlated with
OA and joint progression are AgKS11,12, HA11,13e15, and
COMP16e19. Although not as well studied, transforming
growth factor-b1 (TGF-b1) levels measured in the serum
of OA subjects were found, out of 14 serum and urine
biomarkers tested, to be best associated with a change in
clinical assessments over a 1-year period20.
Whilemostbiomarkerstudiesattempt todistinguishpatients
who have OA from the non-arthritic population, a few studies
have used biomarkers to predict progression11,13e18,21,22.
Most of these studies are limited by their cross-sectional
nature, and those that are longitudinal are observational.
Hence, there are little data available on the effects of a thera-
peutic intervention on changes in biomarker levels.
The objective of the present study was to determine the
correlation of selected biomarkers with clinical outcome
measures in an intervention study using serum samples
collected from the Arthritis, Diet and Activity Promotion Trial
(ADAPT) participants. ADAPT was an 18-month single blind
randomized clinical trial designed to determine if exercise
and dietary weight loss, alone or in combination, were
more effective than usual care in improving pain and func-
tion in older overweight and obese adults with knee OA23.
Both groups receiving the D intervention lost on average
of about 5% body weight and the primary outcome, self-
reported physical function ascertained by Western Ontario
and McMaster Universities Osteoarthritis Index (WOMAC),
showed signiﬁcant improvements of 24% in the diet plus
exercise (Dþ E) group and 18% in the D only group. The
present study reports data on the effects of the interventions
on serum biomarkers, speciﬁcally: AgKS, HA, COMP and
TGF-b1, and their correlations with outcome measures.MethodsPARTICIPANTSDetails of the ADAPT study were previously published23,24. Brieﬂy, 316
patients, aged 60 years and older with a body mass index (BMI) of 28 and
above, who had clinical evidence of knee OA and who met the study criteria,
were assigned to one of the four therapeutic intervention cohorts: healthy-
lifestyle (HL, control group), D, E and DþE. The HL intervention consisted
of a regular group meeting to provide attention, social interactions and health
education. The D intervention was a behavior modiﬁcation type intervention
designed to produce a group average of 5% weight loss. The E intervention
consisted of a combination of aerobic (walking) and resistance training for
a total of 1 h three times a week. Participants in the Dþ E group received
a combination of the D and E interventions.
For all interventions, self-reported physical function (WOMAC function, pain
and stiffness), measures of mobility (stair climb time and 6-min walk distance),Table
Demographics of ADAPT subjects utilized for
DþE (N¼ 46) D (N¼ 48)
Male 9 (19) 14 (30)
White 35 (74) 39 (81)
Age (years) 67.80 (0.95) 68.51 (0.83)
Weight (lbs) 194.8 (4.6) 208.4 (5.0)
BMI (kg/m2) 33.10 (0.67) 33.64 (0.59)weight loss and knee radiographs (medial JSWandKellgreneLawrence [KeL]
score) were the outcome measures used as previously described in detail23.
Outcome measures were determined at baseline, 6 and 18 months except
for the radiographs which were obtained only at baseline and 18 months.BIOMARKER MEASUREMENTSAfter the participants had fasted overnight, blood was collected by
venipuncture in the morning (between 07:00 AM and 09:00 AM) at baseline
and after 6 and 18 months of intervention. Serum was frozen at 80C until
analyzed. Of the 316 subjects in ADAPT, sufﬁcient serum for biomarker
measures was available from all three time points in 193 subjects. In the
present study, the clinical and radiological outcomes were analyzed for these
193 subjects. HA was measured using a well-characterized sandwich
enzyme linked immunosorbent assay (ELISA) technique25. Brieﬂy, the
procedure utilizes an anti-KS monoclonal antibody (1/20/5-D-4; MP Biomed-
icals, Irvine, CA, USA) to differentiate between the coated aggregating rat
chondrosarcoma proteoglycan, which captures HA, and the AgKS-bearing
aggregating proteoglycan added subsequently. AgKS was quantiﬁed by
a previously described ELISA technique26,27 that includes an inhibition
step and also utilizes monoclonal antibody 5-D-4.
COMP was measured using the AnaMar COMP ELISA (AnaMar Medical
AB Bangardsgatan, Uppsala, Sweden). The COMP ELISA is a solid-phase,
two-site enzyme immunoassay, based on a direct sandwich technique in
which two monoclonal antibodies are directed against separate antigenic
determinants on the COMP molecule28. The TGF-b1 level was measured
using a highly sensitive ELISA (Quantikine Human TGF-b1 kit from R&D
Systems Inc., Minneapolis, MN, USA). This assay also employs the quanti-
tative sandwich enzyme immunoassay technique and uses an anti-TGF-b1
monoclonal antibody and a polyclonal antibody against TGF-b1 conjugated
to horseradish peroxidase29.
All samples were measured in duplicate, and the average of the two
values was used for data analyses. Duplicate samples that did not provide
a coefﬁcient of variation <15% were reanalyzed. The intra-assay and
inter-assay variations of the tests are as follows: HA (intra: <4% and inter:
<6%); KS (intra: <3% and inter: <4%); COMP (intra: 1.7e3.0% and inter:
1.8e4.2%); and TGF-b1 (intra: 3.7% and inter: 9.8e12.8%).STATISTICAL ANALYSISStatistical analyses were performed using SAS software version 8 (SAS
Institute, Cary, NC, USA). A signiﬁcant level of 0.05 was adopted for all com-
parisons. Descriptive statistics were calculated for each intervention group
(HL, D, E and DþE) at baseline. Values were reported as means standard
error (SE) unless otherwise indicated. Logarithmic transformations of the bio-
marker results to satisfy the model assumptions (normally distributed errors
and linear relations) were tested, however, the results did not change when
compared to non-log transformed values. Hence, non-transformed data were
reported. Analysis of variance and c-square tests were used to determine
differences among baseline characteristics between intervention groups.
The effects of diet and/or exercise programs on disability, physical func-
tion, pain, and measures of mobility measured at 6 and 18 months post-ran-
domization were determined by repeated measures analysis of covariance.
All follow-up information was analyzed using SAS PROC MIXED (SAS Insti-
tute, Cary, NC, USA). Analyses of group differences were adjusted for the
pre-randomization levels of baseline values of the outcome being analyzed
and by age, gender and BMI. A random effect of subjects that accounted
for the within-subject correlation at the repeated measurements was included.
Estimates of intervention effects were obtained at each follow-up observation.
To test the consistency of intervention effects during the follow-up period,
tests of time of follow-up by intervention effects were conducted. When
time-by-intervention interactions were non-signiﬁcant, average, intervention
effects over the follow-up period were estimated and tested for signiﬁcance.
Pearson’s correlation coefﬁcients were used to examine the relationship
between biomarkers and BMI, WOMAC function, WOMAC pain, WOMACI
biomarker studies, by intervention arm
E (N¼ 46) Control (N¼ 53) P value
N (%)
15 (32) 19 (38) 0.24
38 (81) 45 (85) 0.62
Mean (SE)
68.67 (0.86) 68.94 (0.83) 0.82
196.2 (4.3) 207.8 (5.3) 0.08
33.65 (0.86) 34.26 (0.73) 0.72
Table II
Outcome measures at baseline of ADAPT subjects utilized for biomarker studies, by intervention arm
DþE (N¼ 46) D (N¼ 48) E (N¼ 46) Control (N¼ 53) P value
Mean (SE)
KeL score 2.52 (0.14) 2.54 (0.11) 2.50 (0.13) 2.51 (0.13) 0.99
WOMAC function 23.38 (1.76) 17.76 (1.74) 25.33 (1.74) 22.42 (1.67) 0.02
WOMAC pain 6.33 (0.53) 5.11 (0.53) 7.39 (0.53) 6.42 (0.51) 0.03
WOMAC stiffness 3.53 (0.22) 2.78 (0.22) 3.87 (0.22) 3.36 (0.21) 0.01
Distance walked (ft) 1472 (46.9) 1392 (38.7) 1535 (48.9) 1485 (44.6) 0.17
Stair climb time (s) 9.14 (0.64) 9.12 (0.84) 9.90 (1.55) 9.85 (0.82) 0.91
JSW_LA (mm) 4.89 (0.20) 4.70 (0.17) 4.63 (0.22) 4.72 (0.18) 0.81
JSW_MED (mm) 3.34 (0.24) 3.17 (0.21) 3.47 (0.22) 3.23 (0.24) 0.80
ft¼ Feet; s¼ seconds; LA¼ lateral; MED¼medial; mm¼millimeters.
1049Osteoarthritis and Cartilage Vol. 16, No. 9stiffness, 6-min walk distance, stair climb time, JSW and the KeL score at
baseline. Repeated measures analysis of covariance was also used to
investigate the relationship between outcome measures and baseline
biomarkers. The same covariates as above were included in the models,
except that BMI was not added to the model for weight. The slope for
each biomarker is reported.ResultsEFFECTS OF TIME AND GROUP ASSIGNMENT ON BIOMARKER
LEVELSAnalyses were conducted on data from 193 ADAPT sub-
jects with a baseline blood sample and any follow-up (6- and
18-month) samples. There were no signiﬁcant differences in
any baseline characteristics of these subjects (Table I).
When examining mean baseline outcome values for all sub-
jects tested, participants in the D group tended to have lower
WOMAC function (P¼ 0.02) pain (P¼ 0.03) and stiffness
(P¼ 0.01) (Table II). All four groups showed similar levels
of biomarkers at baseline (Fig. 1).
Biomarker levels remained relatively stable during the 18
months of the study (Fig. 1 and Table III), except for AgKSCartilage oligomeric protein 
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Fig. 1. Biomarker levels by group assignment over the course of the stud
assays in serum samples obtained from ADAPT subjects at baseline
¼DþE; anlevelswhich, averagedoverall groups,decreasedsigniﬁcantly
over time (P¼ 0.02). Statistically signiﬁcant differences
between groups were present for mean levels of COMP
(P¼ 0.04) and TGF-b1 (P¼ 0.02) (Table III). Pair-wise
comparisons revealed that participants in the E group had sig-
niﬁcantly higher levels of COMP than those in the D and E
groups (P¼ 0.01) and in the control group (P¼ 0.03). TGF-
b1 levels in theDgroupweresigniﬁcantly lower than in thecon-
trol group (P¼ 0.003) and in the D and E groups (P¼ 0.04).
These group differences did not vary signiﬁcantly over time.OUTCOME MEASURES AND LEVELS OF BIOMARKERSThere were no statistically signiﬁcant correlations be-
tween baseline outcome measures and baseline levels of
biomarkers (Table IV), except for KeL scores, which were
positively associated with HA (r¼ 0.35, P¼ 0.0001) and
negatively correlated with TGF-b1 (r¼0.19, P¼ 0.01). In
addition, medial JSW was also associated with HA
(r¼0.23, P¼ 0.004). Slopes for the associations between
follow-up outcomes and baseline levels of biomarkers
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y. The levels of the indicated biomarkers were measured by ELISA
, 6 months, and 18 months. ¼ healthy life-style control; ¼D;
d ¼E.
Table III
Biomarker levels measured at 6 and 18 months, by intervention arms, adjusted for baseline values, age, gender and BMI, mean (SE)
Outcomes DþE D E Control P value*
6-Month
(N¼ 46)
18-Month
(N¼ 46)
6-Month
(N¼ 48)
18-Month
(N¼ 48)
6-Month
(N¼ 45)
18-Month
(N¼ 45)
6-Month
(N¼ 52)
18-Month
(N¼ 53)
Grp Time
HA (ng/ml) 42.28 (3.79) 45.33 (3.63) 46.95 (3.64) 44.21 (3.44) 45.68 (3.67) 43.45 (3.54) 40.46 (3.58) 47.67 (3.35) 0.99 0.50
AgKS
(ng/ml)
310.22 (7.62) 310.93 (7.32) 312.61 (7.29) 306.38 (6.90) 322.79 (7.35) 314.11 (7.09) 308.67 (7.17) 286.66 (6.71) 0.07 0.02
COMP (U/l) 10.80 (0.49) 11.81 (0.46) 11.58 (0.47) 12.21 (0.44) 12.77 (0.46) 12.84 (0.44) 11.75 (0.45) 11.72 (0.42) 0.04 0.10
TGF-b1
(ng/ml)
38.89 (1.14) 39.06 (1.07) 36.40 (1.08) 36.65 (1.01) 37.63 (1.08) 38.46 (1.04) 40.93 (1.04) 39.41 (0.98) 0.02 0.87
*Interactions for group and time not statistically signiﬁcant.
1050 S. D. Chua et al.: Effect of an exercise and dietary intervention on serum biomarkers(Table V). Only weight was signiﬁcantly associated with
AgKS (slope¼ 0.02, P¼ 0.01).
There were a few weak but signiﬁcant associations
between the change in biomarker levels and change in
outcome measures at 18 months (Table VI). These were
for change in weight with change in AgKS (P¼ 0.03) and
COMP (P¼ 0.02) and for change in WOMAC pain and
change in AgKS (P¼ 0.04).Discussion
There are very little data in the literature about the effects
of therapeutic interventions on biomarker levels in an OA
population and how outcome measures commonly used in
clinical trials might correlate with these levels. In this study
of participants in an exercise and weight loss intervention,
we found that the serum levels of HA, COMP, and TGF-
b1 remained relatively stable during the 18-month interven-
tion period while there was an overall slight decline in
AgKS. Any differences observed between intervention
groups were quite minimal.
The most consistent and strongest correlations noted in
the present study between biomarker levels and clinical out-
come measures were noted with HA and radiographic mea-
sures of OA. Serum HA levels at baseline were negatively
correlated with medial JSW and were positively correlated
with the KeL score. These ﬁndings are consistent with other
studies that have shown similar correlations between HA
levels and radiographic OA13e15,30. Serum levels of HA in
people with knee OA are thought to reﬂect the level of syno-
vial inﬂammation because HA is produced by synovial cells
and inﬂammation in the synovium may allow greater
amounts to enter the systemic circulation5.
Our study also showed a signiﬁcant but weak negative
correlation between baseline TGF-b1 levels and KeL score.
TGF-b has anabolic effects on cartilage that might accountTable I
Correlation of baseline biomarker levels with b
Outcomes HA Ag
WEIGHT 0.05 (0.49) 0.04
WOMAC function 0.12 (0.11) 0.03
WOMAC pain 0.09 (0.21) 0.12
WOMAC stiffness 0.11 (0.12) 0.07
Distance walked 0.02 (0.78) 0.09
Stair climb time 0.05 (0.54) 0.13
JSW lateral 0.08 (0.32) 0.11
JSW medial 0.23 (0.004) 0.02
KeL score 0.35 (0.0001) 0.06
Values shown are correlation coefﬁcients followed by P values in parefor a negative association with systemic levels and KeL
score, but it has also been implicated in osteophyte forma-
tion in OA31,32. Separate osteophyte scores would have
been of interest to correlate with levels of TGF-b but were
not available. Our results failed to conﬁrm previous work
suggesting that serum TGF-b might serve as a marker for
clinical outcomes in OA20.
The effect of weight loss on OA biomarkers has not been
previously studied and most reports on the effects of exer-
cise have been on biomarkers in healthy athletes or endur-
ance runners. Sweet et al. found no differences in the
serum levels of AgKS in marathon runners before and after
the completion of a marathon run33 and showed that serum
AgKS levels decreased during periods of immobilization,
but rose after return to ambulation34. Serum levels of
COMP have been shown to increase just after exercise
and return to baseline levels after 30 min and with no in-
crease in baseline levels noted after 6 weeks of an exercise
program35. In two recent studies using serum samples from
the ADAPT subjects, we have shown that the dietary weight
loss but not the E intervention signiﬁcantly reduced levels of
the inﬂammation markers, C-reactive protein, IL-6, and
soluble tumor necrosis factor a receptor 136, and reduced
the levels of the adipokine leptin37. In the present study,
only weak correlations were noted with change in AgKS
and COMP and change in weight over18 months.
Although serum COMP has been widely studied as a po-
tential OA biomarker5, we did not ﬁnd that COMP levels at
baseline, 6 or 18 months correlated with either subjective or
objective outcome measures other than the change in
weight. In the Johnston County Osteoarthritis Project, levels
of COMP varied by ethnicity and sex and were associated
with age, BMI and radiographic OA38. Our study did not
ﬁnd any signiﬁcant differences between the levels of
COMP among our subject populations, which were predom-
inantly Caucasian women. Of interest, a recent longitudinal
observational study has shown an association of anV
aseline outcome measures, r (P value)
KS COMP TGF-b1
(0.60) 0.08 (0.29) 0.02 (0.78)
(0.67) 0.07 (0.36) 0.14 (0.07)
(0.10) 0.04 (0.62) 0.09 (0.22)
(0.36) 0.08 (0.31) 0.08 (0.30)
(0.27) 0.15 (0.06) 0.03 (0.71)
(0.07) 0.11 (0.14) 0.09 (0.22)
(0.14) 0.13 (0.10) 0.13 (0.10)
(0.83) 0.06 (0.45) 0.07 (0.38)
(0.46) 0.01 (0.89) 0.19 (0.01)
ntheses.
Table V
Association between baseline biomarker levels and outcome measures, adjusting for age, gender, BMI (except for weight), baseline value,
group and visit
Outcomes HA AgKS COMP TGF-b1
WEIGHT 0.003 (0.023) 0.02 (0.01) 0.12 (0.16) 0.02 (0.08)
0.90 0.01 0.46 0.78
WOMAC function 0.0004 (0.001) 0.001 (0.0004) 0.01 (0.01) 0.0005 (0.005)
0.77 0.16 0.24 0.92
WOMAC pain 0.001 (0.001) 0.003 (0.001) 0.01 (0.01) 0.003 (0.005)
0.38 0.50 0.49 0.46
WOMAC stiffness 0.00002 (0.002) 0.001 (0.001) 0.01 (0.01) 0.004 (0.01)
0.99 0.03 0.22 0.45
Distance walked 0.58 (0.63) 0.13 (0.20) 6.5 (4.24) 0.71 (2.00)
0.36 0.53 0.13 0.72
Stair climb time 0.01 (0.01) 0.01 (0.004) 0.08 (0.08) 0.03 (0.04)
0.19 0.08 0.30 0.49
JSW lateral 0.001 (0.002) 0.0002 (0.001) 0.02 (0.01) 0.01 (0.01)
0.67 0.74 0.17 0.52
JSW medial 0.004 (0.002) 0.001 (0.001) 0.01 (0.01) 0.01 (0.01)
0.10 0.46 0.55 0.26
KeL score 0.001 (0.001) 0.0003 (0.0003) 0.01 (0.01) 0.002 (0.004)
0.34 0.35 0.40 0.54
Values shown are beta coefﬁcients (SE) followed by P values.
1051Osteoarthritis and Cartilage Vol. 16, No. 9increase in COMP with increased risk of cartilage loss on
magnetic resonance imaging in subjects with knee OA39.
Our radiographic measure of JSW on plain ﬁlms would be
unlikely to detect a similar association given the relatively
small sample size of the current study and the inherent
variability in JSW measures.
There are several important limitations in the present
study. When present, correlations with clinical outcomes,
though statistically signiﬁcant, were relatively weak.
Because this was an exploratory study, we examined all re-
sults with P values< 0.05. Because multiple comparisonsTable V
Association between change (Chg) in biomarker levels at 18 months and
and P va
Outcomes HA-Chg AgK
WEIGHT-Chg 0.05 (0.04) 0.0
P¼ 0.20 P¼
WOMACFUNC-Chg 0.004 (0.003) 0.00
P¼ 0.12 P¼
WOMACPAIN-Chg 0.001 (0.003) 0.00
P¼ 0.64 P¼
WOMACSTIF-Chg 0.001 (0.003) 0.000
P¼ 0.69 P¼
DISTANCE-Chg 0.55 (1.24) 0.0
P¼ 0.66 P¼
STCLTIME-Chg 0.01 (0.03) 0.00
P¼ 0.56 P¼
JSW_LA-Chg 0.0001 (0.002) 0.000
P¼ 0.98 P¼
JSW_MED-Chg 0.004 (0.002) 0.00
P¼ 0.08 P¼
SCORE-Chg 0.001 (0.001) 0.000
P¼ 0.70 P¼
Values shown are beta coefﬁcients (SE) followed by P values.were examined, some of the apparent signiﬁcant observa-
tions may have occurred by chance alone. Also, recent
work has suggested that measurement of markers that re-
ﬂect cleavage of type II collagen, such as CTX-II, may serve
as better OA biomarkers than those measured here22,40,41
although this is still controversial42. However, the most
promising of these assays require measurements in urine
and only serum samples were collected in the present
study. Finally, as with most biomarker studies in OA, a major
limitation is that a systemic measure is being correlated with
local disease activity. About 55% of the subjects in theI
change in outcome measures at 18 months. Beta coefficient (SE)
lue
s-Chg COMP-Chg TGF-b1-Chg
4 (0.02) 0.68 (0.29) 0.02 (0.15)
0.03 P¼ 0.02 P¼ 0.89
2 (0.001) 0.03 (0.02) 0.01 (0.01)
0.15 P¼ 0.13 P¼ 0.92
3 (0.001) 0.03 (0.02) 0.02 (0.01)
0.04 P¼ 0.15 P¼ 0.79
3 (0.001) 0.03 (0.02) 0.003 (0.01)
0.85 P¼ 0.25 P¼ 0.79
3 (0.60) 0.076 (9.9) 5.5 (5.1)
0.96 P¼ 0.94 P¼ 0.28
6 (0.01) 0.23 (0.20) 0.02 (0.11)
0.60 P¼ 0.26 P¼ 0.85
1 (0.001) 0.04 (0.02) 0.003 (0.01)
0.91 P¼ 0.05 P¼ 0.81
1 (0.001) 0.02 (0.02) 0.004 (0.01)
0.65 P¼ 0.34 P¼ 0.68
3 (0.001) 0.001 (0.01) 0.01 (0.01)
0.60 P¼ 0.92 P¼ 0.12
1052 S. D. Chua et al.: Effect of an exercise and dietary intervention on serum biomarkersADAPT study reported having arthritis in more than one
joint23 but the clinical and radiographic outcome measures
focused on knee OA.
In conclusion, the present study showed that serum
levels of four potential biomarkers were relatively stable
during the 18-month intervention. Previous observations
that worse radiographic knee OA correlates with higher
HA serum levels were conﬁrmed. Based on the recent
suggested classiﬁcation criteria of biomarkers (burden of
disease, investigative, prognostic, efﬁcacy of intervention,
and diagnostic)43 the only marker in the present study
that could be classiﬁed would be HA as a marker for burden
of disease. Although it was not possible to conclude from
the biomarker measures that the D and E interventions
improved joint structures, the ﬁnding of little change in
levels of the four markers over the course of the study is
consistent with the premise that the interventions did not
result in measurable harm to the joints. This was a potential
concern with overweight and obese subjects in an exercise
program that included weight-bearing exercises, which re-
sult in periods of increased joint loading.Conﬂict of interest
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